Pharmaceutical TechnologyOriginal article
Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers
PartnershipPositive
AI Analysis
Summary
Gilead and Vir have entered a $1.9bn agreement to develop next-generation T-cell engagers. The deal follows Gilead's earlier entry into the modality through its acquisition of autoimmune-focused Ouro Medicines.
Outcome Details
$1.9bn pact between Gilead and Vir to develop next-generation T-cell engagers
Importance:7/10
Sentiment:
0.60
T-cell engagerspartnershipcollaborationGileadVir
Read the original article
Published by Pharmaceutical Technology on October 15, 2026 1:30 PM